The world's only one has been authorized by regions such as the United States, the United Kingdom and the European Union, and can be used to prevent drugs in Hainan Province, China before the exposure of coronary disease.This drug is a neutralized antibody EVUSHELD developed by Astra Corporation, which has been approved by special items in the country.
According to the First Financial Report, EVUSHELD has two stitches per dose at a price of 13,300 yuan (RMB, Same, S $ 2778.34).This long -acting neutralized antibody drugs will be preferentially applied to the infection of low -immune function. Due to scarcity of supply, it is still difficult to find in the global market.
Haikou Customs released news on the 5th that the Customs of Boao Airport, which belongs to Haikou Customs, recently completed the approval of special items for immigrants for the first import of neutralized antibodies in mainland China.
Evusheld did not get the mainland approved listing, but according to the "National Nine Articles" policy, EVUSHELD can be used in the international medical tourism area of Boao Le City, Hainan, but cannot be settled by medical insurance.
At present, there are two hospitals in Hainan that can make appointments for medication. Priority is to be applied to people with damage to immune function or low immunity. Users must be over 12 years old and weigh less than 40 kilograms.The two hospitals revealed that more than ten people have registered for appointment.The hospital revealed that although pharmaceuticals should be used by providing low immune function, a large part of the currently registered and applied is students who want to go abroad.
Evusheld has entered Hong Kong first.On April 24th, the Hospital Authority introduced that the first batch of more than 190 doses of Aisley Coronary Coronary Coronary Anti -antibody drug EVUSHELD arrived in Hong Kong. It would give priority to weak immune and transplanted patients.
Asleycom introduced that EVUSHELD clinical trials show that the risk of infection with new crown virus in drug use can be reduced by 77%to 83%, and the protection effect lasted at least six months.For multiple mutant plants, including Omircor Ronter BA.4 and BA.5, Astraikon is also developing the next generation of multi -type preventive drugs.
Asleykang has not disclosed the further listing plan of EVUSHELD in China in the future.
However, due to the high price of Evusheld, industry insiders believe that because they cannot pay for medical insurance at their own expense, they may not be widely accepted.In the future, there will be price negotiations when the drug approval enters the market.
